# Arrivent (AVBP) — News

AVBP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/avbp/news

## Recent headlines

- [Arrivent announces first patient dosed with novel tetravalent MUC16/NAPI2B dual target ADC, ARR-002](https://www.ainvest.com/news/arrivent-announces-patient-dosed-tetravalent-muc16-napi2b-dual-target-adc-arr-002-2610) — AInvest Wire, Oct 12, 2026
  Arrivent recently announced the first patient has been dosed in a clinical trial evaluating its novel tetravalent MUC16/NAPI2B dual target antibody-drug conjugate (ADC), ARR-002. The trial is designed to assess safety, tolerability, pharmacokinetics, immunogenicity , and antitumor activity of…
- [Arrivent Biopharma, Inc.: H.C. Wainwright cuts target price to $27 from $47](https://www.ainvest.com/news/arrivent-biopharma-wainwright-cuts-target-price-27-47-2610) — AInvest Wire, Oct 8, 2026
- [Arrivent Biopharma, Inc.: Clear Street cuts target price to $22 from $47](https://www.ainvest.com/news/arrivent-biopharma-clear-street-cuts-target-price-22-47-2610) — AInvest Wire, Oct 7, 2026
  Clear Street has revised its price target for Arrivent Biopharma, Inc. (AVBP), reducing it from $47 to $22, reflecting a significant shift in the firm’s outlook for the biopharmaceutical company. The adjustment comes amid ongoing challenges for AVBP, which remains in the development stage and has…
- [Arrivent Biopharma, Inc.: Citigroup cuts target price to $20 from $40](https://www.ainvest.com/news/arrivent-biopharma-citigroup-cuts-target-price-20-40-2610) — AInvest Wire, Oct 7, 2026
  Citigroup has revised its price target for Arrivent Biopharma, Inc. (ARRV), reducing it from $40 to $20, reflecting a 50% decrease in the firm’s projected valuation for the stock. The adjustment follows a reassessment of the company’s near-term financial outlook and market positioning. While the…
- [Arrivent Biopharma, Inc.: Jefferies cuts target price to $18 from $45](https://www.ainvest.com/news/arrivent-biopharma-jefferies-cuts-target-price-18-45-2610) — AInvest Wire, Oct 7, 2026
  Jefferies has revised its target price for ArriVent BioPharma, Inc. (NASDAQ: AVBP) from $45 to $18, reflecting a significant downward adjustment in its valuation outlook for the biotechnology firm. The move comes amid ongoing clinical trials for the company’s lead candidate, firmonertinib, a…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).